Score Overview
Explore the 2021 public Archive ranking โ
Where Arrowhead Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ARWR
2008: 97.7% ยท 2021: 88.9% ยท free through 2021 ยท longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-11-17 | $ 42.99 | โ |
1 Year2025-11-17 | $ 40.15 | 7.07% |
5 Years2021-11-17 | $ 63.74 | -32.55% |
10 Years2016-11-17 | $ 4.51 | 9x |
20 Years2006-11-17 | $ 47.60 | -9.68% |
30 Years1996-11-15 | $ 203.13 | -78.84% |
| Period | Last Price2026-11-17 | 1 Year2025-11-17 | 5 Years2021-11-17 | 10 Years2016-11-17 | 20 Years2006-11-17 | 30 Years1996-11-15 |
|---|---|---|---|---|---|---|
| Price | $ 42.99 | $ 40.15 | $ 63.74 | $ 4.51 | $ 47.60 | $ 203.13 |
| Return | โ | 7.07% | -32.55% | 9x | -9.68% | -78.84% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| 2026 | $ 450M | -$ 724M | $ 1.19B |
| 2025 | $ 829M | $ 919M | |
| 2024 | $ 3M | -$ 599M | $ 680M |
| 2023 | $ 240M | -$ 205M | $ 403M |
| 2022 | $ 243M | -$ 176M | $ 376M |
| 2021 | $ 138M | -$ 140M | $ 367M |
| 2020 | $ 87M | -$ 84M | $ 315M |
| 2019 | $ 168M | $ 67M | $ 258M |
| 2018 | $ 16M | -$ 54M | $ 76M |
| 2017 | $ 31M | -$ 34M | $ 65M |
| 2016 | -$ 81M | $ 85M | |
| 2015 | $ 382K | -$ 91M | $ 98M |
| 2014 | $ 175K | -$ 58M | $ 154M |
| 2013 | $ 290.27K | -$ 31M | $ 28M |
| 2012 | $ 146.88K | -$ 21M | $ 3M |
| 2011 | $ 296.14K | -$ 3M | $ 8M |
| 2010 | $ 620.1K | -$ 5M | $ 6M |
| 2009 | $ 3M | -$ 19M | $ 2M |
| 2008 | $ 1M | -$ 27M | $ 10M |
| 2007 | $ 1M | -$ 29M | $ 24M |
| 2006 | $ 595.46K | -$ 18M | $ 28M |
| 2005 | $ 590.68K | -$ 6M | $ 22M |
| 2004 | $ 196.31K | -$ 2M | $ 9M |
| 2003 | -$ 95.24K | $ 1M | |
| 2002 | $ 2.27K | -$ 246.21K | $ 18.49K |
| 2001 | $ 9.31K | -$ 185.82K | $ 271.00 |
| 2000 | $ 24.88K | -$ 137.55K | $ 1.95K |
| 1999 | $ 37K | $ 593K | $ 124.00 |
| 1998 | $ 60.38K | -$ 165.03K | $ 1.02K |
| 1997 | $ 76.59K | -$ 854.53K | $ 1.17K |

Arrowhead Pharmaceuticals Inc fundamental performance
Between 2006 and 2026, revenue grew from $ 595.46K to $ 450M and net income went from -$ 18M to -$ 724M. Revenue increased in 10 of those 20 years; net income in 8.
Across Arrowhead Pharmaceuticals Inc's full reported history, from 1997 to 2026, revenue grew from $ 76.59K to $ 450M and net income went from -$ 854.53K to -$ 724M. Revenue increased in 44% of the years measured; net income in 37%.
Arrowhead Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.
Membership
Continue ARWRโs history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,187 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio




